Micro Cap
Drug Manufacturers - General
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
|
CANF
26
Can-Fite BioPharma American Depositary Shares
CANF
$4.63M
| $4.63M | $2.16 | 0.46% |
|
27
Calidi Biotherapeutics
CLDI
$2.92M
| $2.92M | $1.13 | 5.83% |
|
28
Matinas BioPharma
MTNB
$2.35M
| $2.35M | $0.1600 | 10.1% |
|
29
Oragenics
OGEN
$2.2M
| $2.2M | $0.4878 | 3.02% |
|
|
HLSQ
30
Tessera Defense and Homeland Security Inc.
HLSQ
$1.43M
| $1.43M | $0.5280 | 0% |
|
Micro Cap Drug Manufacturers - General Stocks at a Glance
Large drug manufacturers sell diversified portfolios of branded medicines backed by deep development pipelines. Patent lives set the clock: blockbuster franchises fund the R&D and acquisitions needed to outrun expirations, supporting durable margins and dividends.
There are 30 micro cap Drug Manufacturers - General stocks — companies in the Drug Manufacturers - General industry with a market cap under $250M — worth a combined $1.2B.
The largest by market cap are Protalix BioTherapeutics (PLX) at $219M, Armata Pharmaceuticals (ARMP) at $139M and Pelthos Therapeutics (PTHS) at $85M.
Among institutional investors, Armata Pharmaceuticals (ARMP) drew the most net new fund positions in Q2 2026: 19 funds opened new positions, taking total fund holders up 8 (18%) quarter-over-quarter.
- Combined market cap: $1.2B across 30 stocks.
- Micro Cap: market cap under $250M.
- Largest constituent: Protalix BioTherapeutics (PLX), $219M market cap.
- Most net new fund positions in Q2 2026: Armata Pharmaceuticals (ARMP), +8 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.